Nippon India Pharma Fund Growth

Nippon India Pharma Fund Growth

Equity
Sectoral
Very High Risk
+20.26%
3Y annualised
-1.70% 1D
1M
6M
1Y
3Y
5Y
All
NAV: 20 Jan '26
₹488.48
Min. SIP amount
Not Supported
Fund size
₹8,264.71 Cr
Expense ratio
1.82%

Holdings (36)

NameSectorInstrumentsAssets
Sun Pharmaceutical Industries Ltd.HealthcareEquity13.02%
Lupin Ltd.HealthcareEquity7.36%
Divi's Laboratories Ltd.HealthcareEquity6.58%
Cipla Ltd.HealthcareEquity6.39%
Dr. Reddy's Laboratories Ltd.HealthcareEquity6.02%
Apollo Hospitals Enterprise Ltd.HealthcareEquity5.53%
Vijaya Diagnostic Centre Ltd.HealthcareEquity3.71%
Medplus Health Services Ltd.HealthcareEquity3.54%
Ajanta Pharma Ltd.HealthcareEquity3.21%
Sai Life Sciences Ltd.HealthcareEquity2.81%
Glaxosmithkline Pharmaceuticals Ltd.HealthcareEquity2.73%
Abbott India Ltd.HealthcareEquity2.61%
Aurobindo Pharma Ltd.HealthcareEquity2.44%
Thyrocare Technologies Ltd.HealthcareEquity2.37%
JB Chemicals & Pharmaceuticals Ltd.HealthcareEquity2.20%
Dr. Lal Pathlabs Ltd.HealthcareEquity2.19%
Alkem Laboratories Ltd.HealthcareEquity2.16%
Narayana Hrudayalaya Ltd.HealthcareEquity2.12%
Ipca Laboratories Ltd.HealthcareEquity2.05%
Mankind Pharma Ltd.HealthcareEquity2.01%
Pfizer Ltd.HealthcareEquity1.92%
Gland Pharma Ltd.HealthcareEquity1.67%
Suraksha Diagnostic Ltd.HealthcareEquity1.27%
Emcure Pharmaceuticals Ltd.HealthcareEquity1.23%
Fortis Healthcare Ltd.HealthcareEquity1.18%
Sanofi Consumer Healthcare India Ltd.HealthcareEquity1.17%
Sanofi India Ltd.HealthcareEquity1.14%
Max Healthcare Institute Ltd.HealthcareEquity1.13%
Syngene International Ltd.HealthcareEquity1.09%
Biocon Ltd.HealthcareEquity1.06%
Anthem Biosciences Ltd.HealthcareEquity0.83%
Akums Drugs And Pharmaceuticals Ltd.HealthcareEquity0.83%
Astrazeneca Pharma India Ltd.HealthcareEquity0.68%
Indoco Remedies Ltd.HealthcareEquity0.52%
Orchid Pharma Ltd.HealthcareEquity0.42%
Concord Biotech Ltd.HealthcareEquity0.18%
See All

Minimum investments

Min. for 1st investment
Not Supported
Min. for 2nd investment
Not Supported
Min. for SIP
Not Supported

Returns and rankings

Annualised returns
Absolute returns
Name3Y5Y10YAll
Fund returns+20.3%+13.7%+13.6%+19.7%
Category average (Equity Sectoral)+22.1%+14.6%+12.0%--
Rank (Equity Sectoral)1251--

Exit load, stamp duty and tax

Exit load

Exit load of 1% if redeemed within 1 month.

Stamp duty on investment: 0.005% (from July 1st, 2020)

from July 1st 2020

Tax implication

If you redeem within one year, returns are taxed at 20%. If you redeem after one year, returns exceeding Rs 1.25 lakh in a financial year are taxed at 12.5%.
Check past data

Fund management

SRB
Sailesh Raj Bhan
Mar 2005 - Present
View details

Education
Mr. Bhan is an MBA (Finance) and CFA.
Experience
Prior to joining Nippon India Mutual Fund, he has worked with Emkay Share & Stock Broker Pvt. Ltd, Shah & Sequeira Invst. Pvt. Ltd, ICFAI- Securities Research Center Analyst - Equity Research.

DDS
Divya Dutt Sharma
Sep 2025 - Present
View details

Education
Bachelor of Commerce, MSC Banking & Finance.
Experience
Prior to joining the Nippon AMC, he was associated with Bhramrishi Mission NGO, Equations LLC, V.K Pamecha and Associates.
Also manages these schemes

LM
Lokesh Maru
Sep 2025 - Present
View details

Education
Bachelor of Technology, CFA, FRM
Experience
Prior to joining the Nippon AMC, he was associated with BlackRock Services India Private Ltd, CRISIL Ltd.
Also manages these schemes

About Nippon India Pharma Fund Growth

Nippon India Pharma Fund Growth is a Equity Mutual Fund Scheme launched by Nippon India Mutual Fund. This scheme was made available to investors on 30 Jun 1995. Sailesh Raj Bhan is the Current Fund Manager of Nippon India Pharma Fund Growth fund. The fund currently has an Asset Under Management(AUM) of ₹7,11,423 Cr and the Latest NAV as of 20 Jan 2026 is ₹488.48. The Nippon India Pharma Fund Growth is rated Very High risk. Minimum SIP Investment is set to ₹100. Exit load of 1% if redeemed within 1 month. ;

Investment Objective

The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies.
Fund benchmarkBSE Healthcare Total Return Index

Fund house

Rank (total assets)#4 in India
Total AUM₹7,11,422.55 Cr
Date of Incorporation30 Jun 1995
Phone+91 022 6808 7000
E-mailNA
Launch Date30 Jun 1995
Address30th Floor, One Lodha PlaceSenapati Bapat Marg, Lower ParelMumbai Mumbai 400013
CustodianDeutsche Bank
Registrar & Transfer AgentKFin Tech
AddressKarvy House, No. 46, 8-2-609/K, Avenue 4, Street No.1 Banjara Hills,